Cookies help us to understand how you use our website so that we can provide you with the best experience when you are on our site. To find out more, read our privacy policy and cookie policy.
Manage Cookies
A cookie is information stored on your computer by a website you visit. Cookies often store your settings for a website, such as your preferred language or location. This allows the site to present you with information customized to fit your needs. As per the GDPR law, companies need to get your explicit approval to collect your data. Some of these cookies are ‘strictly necessary’ to provide the basic functions of the website and can not be turned off, while others if present, have the option of being turned off. Learn more about our Privacy and Cookie policies. These can be managed also from our cookie policy page.
Strictly necessary cookies(always on):
Necessary for enabling core functionality. The website cannot function properly without these cookies. This cannot be turned off. e.g. Sign in, Language
Analytics cookies:
Analytical cookies help us to analyse user behaviour, mainly to see if the users are able to find and act on things that they are looking for. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. Tools used: Google Analytics
Social media cookies:
We use social media cookies from Facebook, Twitter and Google to run Widgets, Embed Videos, Posts, Comments and to fetch profile information.
Share Developing new treatments for leukaemia on FacebookShare Developing new treatments for leukaemia on TwitterShare Developing new treatments for leukaemia on LinkedinEmail Developing new treatments for leukaemia link
Acute Myeloid Leukaemia (AML) is a cancer of the bone marrow. There are many different types, but in most cases the AML cells take over the bone marrow and prevent production of normal red and white blood cells and platelets.
The standard treatment is intensive chemotherapy. Although it is effective at killing the leukaemia cells, they can develop resistance and come back. The chemotherapy also kills healthy blood cells and has unpleasant side effects. There is therefore an urgent need for new, effective and well tolerated therapies for Acute Myeloid Leukaemia.
Our previous research has shown that activation of a chemical pathway called the HIF, or hypoxia-inducible factor pathway, can kill the leukaemia cells. We have developed several drugs which can activate the pathway and they have proven effective in the laboratory setting.
This project aims to increase understanding of these drugs in order to develop a clinical trial for this treatment.
How can you get involved?
This project relies on patients with AML donating blood and bone marrow samples, which would be taken alongside samples needed for their diagnosis and treatment.
How can we best explain the research to patients when we request the samples? Are there any barriers or reasons why patients may choose not to donate these? Please add your ideas below.
Please also add any ideas on how/ where to share this research with relevant groups and networks.
Acute Myeloid Leukaemia (AML) is a cancer of the bone marrow. There are many different types, but in most cases the AML cells take over the bone marrow and prevent production of normal red and white blood cells and platelets.
The standard treatment is intensive chemotherapy. Although it is effective at killing the leukaemia cells, they can develop resistance and come back. The chemotherapy also kills healthy blood cells and has unpleasant side effects. There is therefore an urgent need for new, effective and well tolerated therapies for Acute Myeloid Leukaemia.
Our previous research has shown that activation of a chemical pathway called the HIF, or hypoxia-inducible factor pathway, can kill the leukaemia cells. We have developed several drugs which can activate the pathway and they have proven effective in the laboratory setting.
This project aims to increase understanding of these drugs in order to develop a clinical trial for this treatment.
How can you get involved?
This project relies on patients with AML donating blood and bone marrow samples, which would be taken alongside samples needed for their diagnosis and treatment.
How can we best explain the research to patients when we request the samples? Are there any barriers or reasons why patients may choose not to donate these? Please add your ideas below.
Please also add any ideas on how/ where to share this research with relevant groups and networks.
